These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28616089)

  • 21. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
    Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model.
    Bhat L; Hawkinson J; Cantillon M; Reddy DG; Bhat SR; Laurent CE; Bouchard A; Biernat M; Salvail D
    Eur J Pharmacol; 2018 May; 827():159-166. PubMed ID: 29453947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy.
    Schulze-Neick I; Gilbert N; Ewert R; Witt C; Gruenig E; Enke B; Borst MM; Lange PE; Hoeper MM
    Am Heart J; 2005 Oct; 150(4):716. PubMed ID: 16209972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment with sildenafil, bosentan, or both in children and young people with idiopathic pulmonary arterial hypertension and Eisenmenger's syndrome].
    Raposo-Sonnenfeld I; Otero-González I; Blanco-Aparicio M; Ferrer-Barba A; Medrano-López C
    Rev Esp Cardiol; 2007 Apr; 60(4):366-72. PubMed ID: 17521545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening and treating pulmonary arterial hypertension in a tertiary hospital-based multidisciplinary clinic: the first 200 patients.
    Low AJ; Fowler D; Manghani MK; Young I; Garsia R; Torzillo P; Youssef P; Celermajer DS
    Intern Med J; 2013 Jan; 43(1):32-7. PubMed ID: 22032309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of escalating doses of sildenafil on hemodynamics and gas exchange in children with pulmonary hypertension and congenital cardiac defects.
    Raja SG; Danton MD; MacArthur KJ; Pollock JC
    J Cardiothorac Vasc Anesth; 2007 Apr; 21(2):203-7. PubMed ID: 17418732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
    Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
    Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute endothelin A receptor antagonism improves pulmonary and systemic haemodynamics in patients with pulmonary arterial hypertension that is primary or autoimmune and related to congenital heart disease.
    Apostolopoulou SC; Rammos S; Kyriakides ZS; Webb DJ; Johnston NR; Cokkinos DV; Kremastinos DT
    Heart; 2003 Oct; 89(10):1221-6. PubMed ID: 12975426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings.
    Ivy DD; Rosenzweig EB; Lemarié JC; Brand M; Rosenberg D; Barst RJ
    Am J Cardiol; 2010 Nov; 106(9):1332-8. PubMed ID: 21029834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of iloprost combined with low dose tadalafil in adult congenital heart disease patients with severe pulmonary arterial hypertension: a single-center, open-label controlled study].
    Zhang C; Huang Y; Huang T; Xia C; Huang X; Zhang G; Yao H; Chen J; Chen J; Wu S; Zhuang J
    Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Jun; 42(6):474-80. PubMed ID: 25164220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry.
    Chazova IE; Arkhipova OA; Martynyuk TV
    Ter Arkh; 2019 Mar; 91(1):24-31. PubMed ID: 31090367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome.
    Duffels MG; Vis JC; van Loon RL; Nieuwkerk PT; van Dijk AP; Hoendermis ES; de Bruin-Bon RH; Bouma BJ; Bresser P; Berger RM; Mulder BJ
    Am J Cardiol; 2009 May; 103(9):1309-15. PubMed ID: 19406277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of echocardiographic variables of right ventricular function with exercise capacity after bosentan treatment in patients with pulmonary arterial hypertension: Results from a multicenter, prospective, cohort study.
    Kim H; Bae Lee J; Park JH; Yoo BS; Son JW; Yang DH; Lee BR
    J Clin Ultrasound; 2017 Jan; 45(1):28-34. PubMed ID: 27619758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pulmonary arterial hypertension associated with congenital heart disease.
    D'Alto M; Mahadevan VS
    Eur Respir Rev; 2012 Dec; 21(126):328-37. PubMed ID: 23204121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome.
    D'Alto M; Romeo E; Argiento P; D'Andrea A; Sarubbi B; Correra A; Scognamiglio G; Papa S; Bossone E; Calabrò R; Vizza CD; Russo MG
    Int J Cardiol; 2013 Apr; 164(3):323-6. PubMed ID: 21802156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The acute effects of 30 mg vs 60 mg of intravenous Fasudil on patients with congenital heart defects and severe pulmonary arterial hypertension.
    Ruan H; Zhang Y; Liu R; Yang X
    Congenit Heart Dis; 2019 Jul; 14(4):645-650. PubMed ID: 31166081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
    Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
    BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease.
    Kotlyar E; Sy R; Keogh AM; Kermeen F; Macdonald PS; Hayward CS; McNeil KD; Celermajer DS
    Cardiol Young; 2006 Jun; 16(3):268-74. PubMed ID: 16725066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study.
    Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S
    Heart; 2007 Mar; 93(3):350-4. PubMed ID: 16980516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defects.
    Mehta PK; Simpson L; Lee EK; Lyle TA; McConnell ME; Book WM
    Tex Heart Inst J; 2008; 35(3):256-61. PubMed ID: 18941642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.